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Abstract
Introduction: Recurrent ovarian carcinoma has dismal prognosis, but control of disease and prolonged survival are possible in
some patients. The estimated 5-year survival is 46% for all stages of ovarian cancer, and only 28% for metastasized disease. Notably,
the majority of women with ovarian cancer are diagnosed with stage III or IV disease with a high recurrence rate. As most women with
relapsed or metastatic cancer will die of progressive disease, there is an urgent need for novel therapeutic strategies. The primary aim
of our study is to evaluate safety and toxicity of intraperitoneal infusion of ex vivo-expanded natural killer cells (NK), generated from
CD34+ umbilical cord blood (UCB) progenitor cells, with and without a preceding non-myeloablative immunosuppressive
conditioning regimen in patients suffering from recurrent ovarian cancer. The secondary objectives are to compare the in vivo lifespan,
expansion, and biological activity of intraperitoneally infused NK cell products with or without preparative chemotherapy, as well as
evaluate effects on disease load.
Methods: In this phase I safety trial, 12 patients who are suffering from recurrent ovarian cancer, detected by a signiﬁcant rise in
serum level of CA-125 on two successive time points, will be included. Prior to UCB-NK cell infusion, a laparoscopy is performed to
place a catheter in the peritoneal cavity. The ﬁrst cohort of three patients will receive a single intraperitoneal infusion of 1.5-3109
UCB-NK cells, generated ex vivo from CD34+ hematopoietic progenitor cells obtained from an allogeneic UCB unit, without a
preparative chemotherapy regimen. The second group of three patients will be treated with a similar dose of UCB-NK cells following a
preparative four days non-myeloablative immunosuppressive conditioning regimen with cyclophosphamide and ﬂudarabine (Cy/Flu).
If no severe toxicity is seen in these 6 patients, an extension cohort of 6 patients will be included to answer the secondary objectives.
Discussion: This study investigates the safety of a promising new cellular therapy in a group of patients with a poor prognosis.
Demonstration of safety and in vivo expansion capacity of allogeneic UCB-NK cells in the absence of Cy/Flu pretreatment will provide
rationale for UCB-NK cell infusion after regular second-line chemotherapy.
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Abbreviations: AML = acute myeloid leukemia, CA-125 = cancer antigen, CCMO = Central Committee on Research Involving
Human Subjects, Cy/Flu = cyclophosphamide and ﬂudarabine, DNA = desoxyribonucleic acid, GMP = good manufacturing
practice, GVHD= graft-versus-host disease, HLA= human leukocyte antigen, HPC= hematopoietic progenitor cell, IFN= interferon,
IL= interleukin, IP = intraperitoneal, IV = intravenous, KIR = killer immunoglobulin-like receptor, KWF=Dutch Cancer Society, METC
= medical ethics committee, MHC = major histocompatibility complex, NK = natural killer cells, NSG = NOD/SCID-IL2Rgnull, OC =
ovarian carcinoma, PB = peripheral blood, PBMC = peripheral blood mononuclear cells, PF = peritoneal ﬂuid, PFMC = peritoneal
ﬂuid mononuclear cells, PFS = progression-free survival, Q-PCR = quantitative polymerase chain reaction, RT-PCR = reverse
transcriptase-polymerase chain reaction, TNF = tumor necrosis factor, TRAIL = TNF-related apoptosis-inducing ligand, UCB =
umbilical cord blood, VEGF = vascular endothelial growth factor.
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1. Introduction
Recurrent ovarian carcinoma (OC) remains largely incurable, but
control of disease and prolonged survival can be achieved in some
patients. The estimated 5-year survival is 46% for all stages of
ovarian cancer, and only 28% for metastasized disease.[1]
Notably, nearly 70% of women with OC present with stage
III or IV disease, for which the recurrence rate is 60%–70%. As
most women with relapsed or metastatic cancer will die of
progressive disease, there is an urgent need for novel therapeutic
strategies. Current therapy of relapsed disease consists of 6 cycles
of palliative chemotherapy, which are not always completed due
to side effects or early progression. New drugs include the
antibody bevacizumab and the tyrosine kinase inhibitor
cediranib targeting the VEGF axis, which are used in combina-
tion with gemcitabine and carboplatin chemotherapy. Although
these combinations show improvement of progression-free
survival (PFS), they do not prolong overall survival.[2,3]
Interestingly, accumulating evidence indicates that presence of
immune responses has prognostic value in OC. Inﬁltrating CD8+
T cells and CD56+ NK cells can be detected in OC biopsies, and
strong inﬁltration of CD8+ T cells is correlated with prolonged
survival.[4–7] As most tumors with inﬁltrating CD56+ NK cells
also contain CD8+ T cells, the precise contribution of these
individual populations in mediating antitumor efﬁcacy remains
unclear. Nevertheless, enhanced NK cell frequencies in the
lymphocyte fraction in ascites of advanced OC patients have
been associated with prolonged survival.[8] This emphasizes that
OC patients could beneﬁt from immunotherapeutic strategies.
Therefore, we exploit a unique immunotherapy consisting of
highly powerful allogeneic NK cells ex vivo generated from
hematopoietic progenitor cells (HPCs) obtained from umbilical
cord blood (UCB).
NK cells are key immune effector cells, capable of effectively
killing tumor cells through several killing mechanisms.[9] These
include release of cytotoxic granules containing perforin and
granzymes, TRAIL-dependent cytotoxicity, and activation of
Fas-mediated apoptosis. NK cell activation is tightly regulated by
activating and inhibitory signals from cell surface receptors.[10]
The inhibitory signals are mediated by HLA class I-binding
receptors, including killer cell immunoglobulin-like receptors
(KIRs) and CD94/NKG2A. Since HLA class I molecules are often
lowly expressed on tumor cells,[11–13] these inhibitory receptors
are not engaged. So, in the presence of activating signals, target
cells will be killed (i.e., the “missing-self” concept).[14] These
activating signals are mediated by a wide array of receptors,
includingNKG2D, DNAM-1, natural cytotoxicity receptors (i.e.,
NKp30, NKp44, NKp46), CD94/NKG2C, and KIR with
activating intracellular domains. Ligands for these activating
receptors are expressed predominantly by “stressed” cancer cells,
and not by normal cells. Differential expression of these ligands
between tumor and normal cells determines the tumor reactivity
of NK cells.
In the evolving era of immunotherapy, NK cells are promising
candidates for cellular therapy. Numerous trials have been
launched in the past years, exploring infusion of allogeneic NK
cell products against various cancers.[15,16] Approximately 70%
of these trials target hematological malignancies, particularly
acute myeloid leukemia (AML). Adoptive NK cell therapy plus
low-dose IL-2 after lymphodepleting cyclophosphamide (Cy)/
ﬂudarabine (Flu) conditioning has shown to induce 20%–50%
complete remissions in relapsed/refractory AML patients.[17–20]
Clinical efﬁcacy correlates with in vivo NK cell persistence and
expansion. In addition, NK cell therapy is an emerging therapy
for solid tumors, including OC.[21–23] The ﬁrst trial showed that
intravenous infusion of allogeneic NK cells plus low-dose IL-2
after lymphodepleting chemotherapy resulted in transient in vivo
expansion of NK cells in recurrent OC patients. Notably, most
studies are performed with NK cells enriched from peripheral
blood (PB) of haplo-identical donors, which typically contains
about 30%–70%NK cells with low activation status.[17,18,24] To
generate a more homogenous and well-deﬁned NK cell product,
we have developed methodology for the expansion of NK cells
from UCB-HPCs.[25–27] Recently, we reported that by applying
the aryl hydrocarbon receptor (AHR) antagonist StemRegenin-1
(SR1) and the combination of IL-15 and IL-12, we can generate
highly active NK cells with potent reactivity against hematologi-
cal tumor cells in vitro as well as anti-leukemic effects in vivo
following intravenous administration.[27–29] Preclinical testing
showed that this “next generation” UCB-NK cell product also
effectively kills OC cells and spheroids.[30] In previous homing
studies in NOD/SCID/IL2Rgnull (NSG) mice and patients, it has
been observed that a major part of the NK cell product
accumulates in the liver and lungs 48hours after IV infu-
sion.[31,32] Since in OC patients the disease is conﬁned to the
peritoneal cavity, IP infusion of UCB-NK cells was explored in
NSG mice engrafted with SKOV-3 ovarian tumor nodules in the
abdomen. Interestingly, signiﬁcantly decreased tumor progres-
sion and improved survival of OC-bearing mice were ob-
served.[30] These ﬁndings illustrate that intraperitoneal UCB-NK
cell therapy could be a promising strategy to control OC.
The primary aim of our study is to evaluate safety and toxicity
of intraperitoneal infusion of ex vivo-expanded NK cells,
generated from CD34+ UCB progenitor cells, with and without
a preceding non-myeloablative immunosuppressive conditioning
regimen in patients suffering from recurrent OC. Secondary
objectives are to compare the in vivo expansion, lifespan, and
biological activity of intraperitoneally infusedNK cell products in
patients treated with or without preparative chemotherapy, as
well as evaluate effects on disease load.




The study is designed as a phase I toxicity study in a series of 12
patients suffering from their second recurrence of ovarian,
fallopian tube, or primary peritoneal cancer, detected by an
elevated serum level of CA-125 on two successive time points
with 28 days in between, reaching a level of more than 35U/ml, to
evaluate:
- safety and toxicity of intraperitoneal CD34+ UCB progenitor-
derived allogeneic NK cell infusions with a ﬁxed dose of 1.5–
3109 ex vivo-expanded UCB-NK cells in patients treated
with or without preceding immunosuppressive conditioning
therapy.
Secondary Objectives:
- evaluation of the in vivo expansion and lifespan of UCB-NK
cells following intraperitoneal infusion in patients treated with
or without preceding immunosuppressive conditioning thera-
py.
- exploration of the biological and clinical activity of UCB-NK
cell infusion in study participants.
2.2. Study design
This is a prospective phase I toxicity study in a single center. In
this trial, a total of 12 patients divided over 4 cohorts, suffering
from a second recurrence of ovarian, fallopian tube, and primary
peritoneal cancer, will be infused with ex vivo-expanded
allogeneic UCB-NK cells. In a classical three-by-three design,
in the ﬁrst two cohorts of three patients, the safety and toxicity of
intraperitoneally infused UCB-NK cells in the absence or presence
of Cy/Flu pre-treatment will be studied. The question whether the
chemotherapeutic preconditioning regimen is necessary will be
addressed in the extension cohorts of three patients without and
three patients with a preparative non-myeloablative immuno-
suppressive chemotherapy regimen. This means that cohort 1 gets
NK cell without Cy/Flu pretreatment, cohort 2 NK cells with
Cy/Flu, cohort 3 NK cells without Cy/ﬂu, and cohort 4 again NK
cells with Cyﬂu pretreatment, see Fig. 1.
2.3. Study schedule
The trial starts in the beginning of 2019. The estimated time of
accrual is 30 months. The estimated study completion date is July
2021, for ﬁnal data collection and secondary outcome measures.
2.4. Statistics
This study has a three-by-three design, with 2 extension cohorts
of 3 patients. A total of 3 patients will be included into each
treatment arm in order to appropriately determine UCB-NK cell
treatment-related toxicity. To answer the other key question
whether Cy/Flu preconditioning is required for successful UCB-
NK cell engraftment and expansion in the peritoneal cavity, we
will perform statistical analyses on the immunomonitoring
results. The proportion of patients with NK cell expansion as
well as the number of NK cells in the peritoneum and blood will
be statistically compared between cohorts 1 and 3 (without Cy/
Flu) and cohorts 2 and 4 (with Cy/Flu) using the Mann–Whitney
U-test. Using the statistical programR, we calculated that a group
size of 6 patients per cohort is sufﬁcient to evaluate whether
preconditioning is required or not. We estimated that precondi-
tioning results in a frequency of 50 ± 20% UCB-NK cells IP
at day 7and/or 14 determined by ﬂow cytometry and DNA
Figure 1. Flow chart study design. In this ﬂowchart, all possible decisions in (dis)continuation of the study are outlined. Toxicity (tox) limits are described in the text.
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chimerism analyses. In case NK cell expansion is >3-fold lower,
i.e., 15%±20%∗ in patients not treated with preconditioning, this
will be a statistically less effective treatment at a signiﬁcance level of
0.05andapowerof0.80. Soafter the classic three-by-three toxicity
study, we will continue with the extension cohort of three patients
per group. If no statistical difference is observed in the total of 6
patients treated with versus 6 patients treated without precondi-
tioning,wewill conclude that preconditioning is not required for IP
UCB-NK cell engraftment and expansion in OC patients. In case
<5% of the peritoneal CD56+CD3-cell fraction is of UCB-NK
origin in preconditioned patients (cohort 2), this is considered
unsuccessful and the trial will be stopped. In that case, the
extension cohortwill not be exposed to an ineffective experimental
treatment and chemotherapy. The secondary goal of clinical (CA-
125) response has a descriptive nature. Data management will be
conducted in Castor (Castor EDC, CIWIT B.V. Amsterdam) in
collaboration with our clinical trial ofﬁce.
2.5. Recruitment
The trial is expected complete recruitment within 30 months.
Participants will be recruited from the Radboud University
Medical Center and referred from the oncologic region, the south
east Netherlands. After obtaining informed consent, patients will
be screened for inclusion and exclusion criteria (Table 1). After
fulﬁlling all eligibility criteria, patients will be enrolled in the
study.
2.6. Study intervention
This study is a phase I toxicity trial, using ex vivo-generated NK
cells from CD34+ UCB cells of allogeneic partially HLA-matched
donors. These ex vivo-generated allogeneic UCB-NK cells will be
infused intraperitoneally into patients suffering from recurrent
ovarian, fallopian tube, or peritoneal cancer treated with or
without Cy/Flu preconditioning. This immunosuppressive con-
ditioning regimen is often applied with intravenous NK cell
infusion to prevent direct rejection, but might not be required in
case of IP administration. The investigational CD56+CD3- UCB-
NK cell products will be ≥70% pure and almost devoid of CD3+
T cells (i.e., <1105cells/kg body weight), thereby minimizing
the risk of allogeneic T cell-mediated GVHD. NK cell therapy is
combined with IL-2 cytokine support, at a dose of 6106units/
dose, 3 times a week with a total of 6 dosages. Study participants
will undergo clinical and immunological evaluation
2.6.1. Laparoscopy. To allow infusion of the UCB-NK cells in
the abdominal cavity, a single lumen 9.6fr attachable silicone
catheter (BardMedical) is placed per laparoscopy. If there are too
many adhesions to reach 5 out of 9 compartments of the
abdominal cavity, no catheter is placed and this patient will be
excluded from further study treatments.
2.6.2. Pretreatment. All patients will receive an intraperitoneal
infusion of 1.5–3109 allogeneic NK cells generated ex vivo from
CD34+ cells obtained from a UCB unit. This dosage is based on
results of published trials with PB-enriched NK cells and our
previous UCB-NK trial in elderly AML patients.[29] Miller et al
are currently executing a trial on peritoneal infusion of enriched
PB-NK cells with IL-2 support in ovarian carcinoma patients
(NCT02118285) and a trial on intraperitoneal FATE-NK100
cells (NCT03213964). IP infusion might be a valuable strategy,
since the immunologic environment in the abdomen is completely
different from the situation in blood. The hypothesis is that our
UCB-NK cell product can survive and expand in the abdominal
cavity without requiring a preparative lymphodepleting chemo-
therapy regimen. However, lymphodepleting chemotherapy is
currently the standard clinical practice for adoptive cellular
therapy in cancer patients. In the ﬁrst cohort, toxicity of UCB-NK
cell therapy with IL-2 support will be monitored. The second
cohort of 3 patients will receive a non-myeloablative immuno-
suppressive preparative regimen of cyclophosphamide (900mg/
m2/day) and ﬂudarabine (30mg/m2/day) on days 6, 5, 4, 3.
Ample experience with this preparative conditioning regimen is
present in our transplant center where patients suffering from
multiple myeloma and high-gradeNon-Hodgkin’s lymphoma are
treated with this regimen.[29,33] In addition, in our trial with the
ﬁrst generation UCB-NK cell product in elderly AML patients, no
severe toxicity was observed. Currently, Cy/Flu is the standard
preparation for cellular adoptive therapy. To evaluate potential
differences in expansion and lifespan of UCB-NK cells in the
abdominal cavity in patients treated with or without myeloa-
blative preconditioning, an extension cohort of 3 patients per
group will be performed, thereby obtaining 6 patients per group.
2.6.3. UCB-NK cells. In eligible patients, UCB-NK cell products
will be administered IP at a dose of minimum 1.5109 and
Table 1
In- and exclusion criteria.
Patient inclusion criteria Patient exclusion criteria
Patients suffering from their second recurrence of ovarian, fallopian tube, or
primary peritoneal cancer, with an elevated serum level of CA-125 on two
successive time points with 28 days in between, reaching a value of more than
2 times nadir and above 35 U/ml without gastrointestinal symptoms.
Patients with active infections (viral, bacterial, or fungal) that requires speciﬁc therapy.
Acute anti-infectious therapy must have been completed within 14 days prior to
study treatment
Able to undergo laparoscopic IP port placement and IP treatment administration Laparoscopic adhesion score >4 out of 9.
Adequate organ function Severe cardiovascular disease (arrhythmias requiring chronic treatment, congestive
heart failure, or symptomatic ischemic heart disease
Age 18 years or older Severe pulmonary dysfunction (CTCAE III-IV)
Age under 76 years. Severe renal dysfunction (MDRD<50)
Karnofsky performance status >70% Severe hepatic dysfunction (serum bilirubin or transaminases > 3 times normal level)
Life expectancy > 6 months Severe neurological or psychiatric disease
At least 28 days after last anticancer treatment, before start of preparative
regimen
Patients on immunosuppressive drugs
Written informed consent
Availability of a partially HLA-matched UCB unit
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maximum 3109 UCB-NK cells. In the ﬁrst cohort, UCB-NK
cells will be infused three days after the Cy/Flu regimen. The
UCB-NK cell dosage is based on our study in elderly AML, where
we demonstrated that Cy/Flu conditioning followed by adminis-
tration of the UCB-NK cell product at a dose 3107/kg body
weight, i.e., 3109 total cells in a patient of 100kg, was safe
and did cause neither GVHD nor severe toxicity. Here, we want
to investigate whether UCB-NK cells are safe to administer
intraperitoneally in OC patients, as this is the standard route of
chemotherapy administration in ovarian carcinoma therapy to
allow better targeting of the intraperitoneal disease. Intraperito-
neal NK cell infusion may favor NK cells to quickly interact with
the tumor cells, without being trapped in the liver or lungs. Since
the immunologic environment in the abdominal cavity is different
from the environment in blood and lymphoid organs, the
hypothesis is that the UCB-NK cells may survive and expand in
the abdominal cavity without the preparative regimen. Based on
our previous clinical trial and the route of administration, we do
not expect severe toxicity of our allogeneic NK cell product.
2.6.4. IL-2. IL-2 (proleukin) will be co-administered IP to
support NK cell expansion and survival.
2.7. Assessment
Patients will be monitored closely for side effects. This includes
physical examination, blood tests, and peritoneal ﬂuid collection.
All patients will be evaluated intensively for toxicity caused by the
conditioning regimen according to the CTCAE toxicity criteria
and Glucksberg GVHD grade.[34]
2.8. Translational research
To study the immunological response, we will determine the
percentage and absolute number of allogeneic UCB-NK cells in
peripheral blood (PB) and peritoneal ﬂuid (PF) after infusion.
These analyses will be done by ﬂow cytometry and DNA
chimerism analyses. In parallel, we will determine the donor NK
cell engraftment and IL-15 plasma level in blood in the context of
NK cell survival and expansion in the peritoneal cavity. Finally,
we will assess cytolytic activity of NK cells, isolated from
peritoneal ﬂuid, using functional assays.
To assess these biological parameters, PB samples will be taken
on day 0 (prestudy sample) and day 1, 3, 7, 14, 21, 28 and 56
after IP-NK cell infusion. PF samples will be obtained at day 0, 7,
14, and 28. The following immunological tests will be conducted
on blood and IP-wash samples:
2.8.1. Phenotypic analyses of NK cells. To study the effect of
treatment on leukocyte composition, immunophenotyping will
be directly performed on PB samples and PF samples collected
following UCB-NK administration. Using a whole blood
phenotype assay, wewill quantify the proportion of the following
lymphocyte subsets: NK cell subsets (CD3-CD56bright and CD3-
CD56dim), NKT cells (CD56+CD3+), T cell subsets (CD3+CD4+
and CD3+CD8+ T cells in combination with CCR7, CD45RA,
CD27, CD25, CD127, FoxP3), and B cells (CD19+). Absolute
numbers of circulating lymphocyte subsets will be determined by
single-platform ﬂow cytometry analyses using counting beads.
Effective NK cell expansion is deﬁned by presence of≥5%donor-
derived NK cells within the circulating and/or peritoneal cell
fraction at day 7 after infusion. In addition, multicolor ﬂow
cytometry panels will be used to examine the frequency and
phenotype leukocyte subsets in the IP-wash samples. Next to the
above mentioned lymphocyte subsets, we will determine the
proportion of macrophages and CD45-tumor cells. Furthermore,
in both blood and IP-wash samples, the CD56+CD3-NK cell
fraction will be analyzed for the expression of KIRs (CD158a,
CD158b, CD158e), c-type lectin receptors (CD94/NKG2A,
NKG2C, NKG2D), NCR (NKp30, NKp44, NKp46), activation
markers (DNAM-1, CD69, CD16), cytotoxic mediators (Per-
forin, TRAIL), cytokine receptors (CD25, CD127, CD122), and
homing receptors (CXCR3, CD62L).
2.8.2. Enumeration of donor-derived NK cells. To assess in
vivo expansion and persistence of the infused NK cells, we will
perform standard chimerism analysis on DNA derived from PB
and IP-wash samples. DNA will be extracted from blood and IP-
wash samples (Qiagen DNA blood mini kit) and used to
determine the proportion recipient versus donor cells by real-time
quantitative PCR-based single nucleotide polymorphisms (SNP)
that are discriminative for the UCB donor and OC patient.
Patient and donor DNA, collected before infusion, will be used to
identify differential SNP in a panel of polymorphic genes.
Effective NK cell expansion is deﬁned by presence of≥5%donor-
derived NK cells within the circulating and/or peritoneal cell
fraction at day 7after infusion.
2.8.3. Detection of cytokines in plasma. Pre- and postinfusion
plasma and peritoneal wash samples will be evaluated for
cytokine levels by a commercial ELISA or LUMINEX assay. In
cohorts 2 and 4, plasma and PF collected before and after Cy/Flu
conditioning will be examined for enhanced levels of endogenous
cytokines (IL-15, IL-7). In addition, we will determine the levels
of inﬂammatory cytokines (IFN-g, TNF-a, IL-6). Cytokine levels
will be correlated with absolute lymphocyte and NK cell counts,
as well as NK cell chimerism.
2.8.4. Functional activity of UCB-NK cells. To enumerate the
number of NK cells reactive against the patient OC cells, we will
analyze CD107a degranulation and intracellular IFN-g using
ﬂow cytometry. For this, PBMC and peritoneal wash samples will
be cocultured with different OC cell lines (e.g., SKOV-3,
OVCAR, IGROV1), patient-derived ovarian carcinoma cells,
and/or K562 cells (positive control). After overnight incubation,
the percentage CD107a+ and/or IFN-g+ cells within the CD56
+CD3-NK cell population will be determined by ﬂow cytometry.
In parallel, we will evaluate the amount of IFN-g produced by the
stimulated NK cells using ELISA.
2.8.5. Phenotypic analysis and enumeration of tumor cells
present in peritoneal ﬂuid. To study the effect of UCB-NK cell
infusion on the frequency and phenotype (activating and
inhibitory ligands) of tumor cells in the peritoneal ﬂuid, immune
phenotypingwill be performed on the PF samples obtained before
and after UCB-NK administration. This analysis will be
performed on PF samples directly after collection.
2.8.6. Response on residual disease in treated patients. The
effect of NK cell infusion on measurable residual disease will be
investigated by determining CA-125 serum levels.
3. Discussion
This study investigates the feasibility and safety of a promising
new cellular therapy in a group of OC patients with a poor
prognosis. Previous studies exploring different allogeneic NK cell
products showedmild toxicity proﬁles in various cancers.We and
others demonstrated promising clinical effects in AML patients
Hoogstad-van Evert et al. Medicine (2019) 98:5 www.md-journal.com
5
treated with allogeneic NK cell adoptive transfer. However, for
OC, this has not been clearly demonstrated yet. Here, we present
the ﬁrst study investigating our allogeneic UCB-NK cell product,
which is highly activated and exhibits profound cytotoxic
potential, in OC patients following intraperitoneal infusion.
This provides us with the unique opportunity to monitor
immunological responses in the abdominal cavity by consecutive
sampling via an IP catheter.
To explore the therapeutic potential of this UCB-NK cell
product in OC patients, and to conclude whether a myeloablative
immunosuppressive chemotherapeutic regimen is necessary in IP
cellular therapy, there is the need to conduct this phase 1 trial.
The results of this study will provide important information on
the beneﬁt and potential pitfalls of IP cellular therapy, and give
insight in the immunological OC environment during immuno-
therapy through the repeated peritoneal ﬂuid sampling. Demon-
stration of safety of UCB-NK cell therapy and NK cell expansion
in the absence of Cy/Flu pretreatment could provide rationale for
UCB-NK cell infusion after regular second-line chemotherapy.
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